Haematology is at the forefront - interview with EHA President

We asked Professor Antonio Almeida, the President of European Hematology Association about the benefits and perspectives in EHA as a European hematologist, about the highlights of this year EHA congress and about the new Guidelines.

Overall Survival Results of KEYNOTE-564

We asked Professor Stefan N. Symeonides, one of the authors of the KEYNOTE-564 study, about the trial and the new data presented on overall survival at ASCO GU 2024. Adjuvant treatment with pembrolizumab has significantly improved overall survival in patients with clear cell renal cell carcinoma who are at high risk of recurrence after surgery, according to an updated analysis of the KEYNOTE-564 trial.

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

We asked Professor David F. McDermott, investigator of the KEYNOTE-564 study, about the trial and the new data presented on overall survival at ASCO GU 2024.

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

ESMO 2023 Scientific Chair Prof. Silke Gillessen gives a brief summary of this year's congress and invites colleagues to ESMO 2024 in Barcelona next year.

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

Professor Matteo Lambertini highlights the result of the recently published study about the safety of temporarly interrupting endocrine therapy to attempt pregnancy after #Breastcancer. The preliminary results say, this temporary interruption it does not to apper the risk of the patients recurrence. Watch the full interview with Dr. Lambertini  -> https://medicaldigest.org/scientific-contents/interview:whats-new-treatment-breast-cancer-highlights-esmo-bc-2023

The issue of adjuvant vs neoadjuvant treatment

Professor Paolo Ascierto discusses the issue of adjuvant vs neoadjuvant treatment, so whether it's better to use immunotherapy before or after surgery. Watch the full interview with Dr. Ascierto -> https://medicaldigest.org/scientific-contents/interview:hot-topics-melanoma-management

The treatment sequence in metastatic melanoma

Professo Paolo Ascierto discusses the treatment sequence in metastatic melanoma, data shows it is better to start with immuno- than targeted therapy. Watch the full interview with Dr. Paolo Ascierto  -> https://medicaldigest.org/scientific-contents/interview:hot-topics-melanoma-management

Functional Precision Medicine in Oncology

What functional precisionmedicine in oncology means? Professor Anthony Letai explains the new diagnostic option - after he chaired an interesting session about the topic at AACR23.   For more information visit the website of  SFPM: https://www.sfpm.io/ Watch the full interview with Dr. Anthony Letai ->   https://medicaldigest.org/scientific-contents/interview:functional-precision-medicine-oncology

The first mRNA cancer vaccine with pembrolizumab minimizes recurrence rate in melanoma tells Jeffrey Weber clinical investigator

Jeffrey Weber explains the efficacy and safety results of the personalized mRNA cancer vaccine mRNA-4157 with pembrolizumab presented at ACCR23.  It is the first:  - randomized trial that shows benefit for a neoantigen vaccine approach of any type - trial of a mRNA vaccine in melanoma - trial in any cancer that was a phase 2 randomized trial where there was a control arm showing benefit for the addition of the neoantigen vaccine to an established approach in this case of course the PD-1 antibody pembrolizumab Watch the full interview with Dr. Jeffrey Weber ->  https://medicaldigest.org/scientific-contents/interview:first-mrna-cancer-vaccine-pembrolizumab-minimizes-recurrence-rate-melanoma-tells-jeffrey-weber-clinical-investigator

Paradigm shift in the early NSCLC? The role of ICIs in the adjuvant treatment

Professor Federico Cappuzzo gave us an update on the emerging data on the field of lung cancer. There are very important news that were presented during the ESMO, ELCC and EACR. These data are clearly changing the standard of care of patients with early stage Non-Small-Cell Lung Cancer. In this field we have data from two very important trial: the IMpower010 and the KEYNOTE-09.

How will the current therapeutic options change the treatment of RCC in the daily practice?

Prof. Camillo Porta shared his thoughts on the ASCO GU 2022 meeting which focused on the renal cell carcinoma updates. Which were those changes what we can apply in our daily practice?

The role of immune checkpoint inhibitors and VEGF TKIs in the adjuvant treatment of renal cell carcinoma

Prof. David F. McDermott shared his thoughts in the kidney cancer filed. What was the biggest changes in the last six months?

Treatment intensification in the treatment of prostate cancer

Professor Oliver Sartor gave us a talk about the newer concepts around the treatment intensification in prostate cancer, focus a little bit on the newer darolutamide and a PARP inhibitor studies.

Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma

Professor Stefan N. Symeonides gave us a talk about the results from 30-month follow-up of KEYNOTE-564.

State of the art treatment of bladder cancer

Professor Matthew R. Zibelman gave us updates in bladder or urothelial cancers after the recent ASCO GU symposium 2022 from San Francisco.

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer

Professor Ken Kato gave us a talk about longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.